SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the appointment of Matthew Korenberg as Vice President, Finance and Chief Financial Officer. Mr. Korenberg is expected to join Ligand's management team on August 6th.
Mr. Korenberg joins Ligand from NeuroCircuit Therapeutics, a developer of drugs to treat genetic disorders affecting the brain including Down syndrome, where he was founder and Chief Executive Officer. Prior to NeuroCircuit Therapeutics, Mr. Korenberg was with Goldman, Sachs & Co. for 14 years in the firm's New York, London and San Francisco offices. Most recently he was a Managing Director in the healthcare investment banking team, where he advised and financed companies in the biotechnology and pharmaceutical industries. Prior to Goldman Sachs, Mr. Korenberg was a healthcare investment banker at Dillon, Read & Co. Inc. During his time in banking, Mr. Korenberg advised on more than 50 deals representing more than $30 billion of M&A and licensing transactions and raising more than $10 billion in capital. Mr. Korenberg has a BBA in finance and accounting from the University of Michigan.